There are currently 53 active clinical trials seeking participants for Chronic Kidney Diseases research studies. The states with the highest number of trials for Chronic Kidney Diseases participants are California, Texas, Florida and New York.
Mixed-Methods Study of Multidimensional Adversity in Inner-City African American Adults With Chronic Kidney Disease and Type 2 Diabetes Mellitus
Recruiting
The overarching goal of this study is to understand facilitators and barriers to self-care, develop and refine a culturally tailored intervention to improve clinical outcomes, quality of life (QOL), and self-care behaviors in African American adults with diabetic kidney disease (DKD) experiencing multidimensional adversity (MDA) and living in the inner-city.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Medical College of Wisconsin, Milwaukee, Wisconsin
Conditions: Diabetic Nephropathy Type 2 - Uncontrolled, Diabetes Mellitus, Type 2, Chronic Kidney Diseases
A Cardiometabolic Health Program Linked With Clinical-Community Support and Mobile Health Telemonitoring to Reduce Health Disparities
Recruiting
The LINKED- HEARTS Program is a multi-level project that intervenes at the practice level by linking home blood pressure monitoring (HBPM) with a telemonitoring platform (Sphygmo). The program incorporates team-based care by including community health workers (CHWs) and pharmacists to improve the outcomes of multiple chronic conditions (reduced blood pressure (BP), lower blood sugar, and improved kidney function). The LINKED-HEARTS Program will recruit a total of 600 adults with uncontrolled hyp... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/05/2025
Locations: Unity Health Care, Washington, District of Columbia +2 locations
Conditions: Hypertension, High Blood Pressure, Diabetes, Chronic Kidney Diseases
Inspiratory Muscle Strength Training in Chronic Kidney Disease
Recruiting
More than 80% of individuals with chronic kidney disease have concomitant hypertension and the majority fail to achieve blood pressure control \<130/80 mmHg, leading to high risk of cardiovascular diseases and end-stage kidney disease. A stepwise combination of lifestyle modifications and drug therapy is recommended to lower blood pressure; however, adherence to time-intensive lifestyle interventions such as aerobic exercise in patients with chronic kidney disease is poor. This clinical trial se... Read More
Gender:
ALL
Ages:
50 years and above
Trial Updated:
04/29/2025
Locations: University of Colorado - Anschutz Medical Campus, Aurora, Colorado
Conditions: Chronic Kidney Diseases, Hypertension, Aging, Blood Pressure
Ferric Citrate and Chronic Kidney Disease in Children
Recruiting
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20... Read More
Gender:
ALL
Ages:
Between 6 years and 18 years
Trial Updated:
04/29/2025
Locations: University of California, Los Angeles, Los Angeles, California +19 locations
Conditions: Chronic Kidney Diseases
SPYRAL AFFIRM Global Study of RDN With the Symplicity Spyral RDN System in Subjects With Uncontrolled HTN
Recruiting
The purpose of this single-arm interventional study is to evaluate the long-term safety, efficacy, and durability of the Symplicity Spyral system in subjects treated with renal denervation. Additionally, long-term follow-up data will also be collected from eligible subjects previously treated in the SPYRAL PIVOTAL-SPYRAL HTN-OFF MED and SPYRAL HTN-ON MED studies.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/16/2025
Locations: University of Alabama at Birmingham (UAB) Hospital, Birmingham, Alabama +97 locations
Conditions: Hypertension, Vascular Diseases, Cardiovascular Diseases, Chronic Kidney Diseases, Diabetes Mellitus
Pregnancy and Contraception Education in Chronic Kidney Disease (PACE-CKD)
Recruiting
This pilot study will assess the efficacy of a pregnancy and contraception education decision aid (DA) for patients with chronic kidney disease to support decisions about reproductive health, and will assess feasibility and acceptability of the intervention to inform future Research Project Grant (R01) level studies.
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
04/10/2025
Locations: University of Michigan, Ann Arbor, Michigan
Conditions: CKD, Chronic Kidney Diseases
A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease
Recruiting
The purpose of this study is to assess the safety and efficacy (including durability) of up to 2 REACT injections given 3 months (+30 days) apart and delivered percutaneously into biopsied and non-biopsied contralateral kidneys in participants with T2DM and CKD.
Gender:
ALL
Ages:
Between 30 years and 80 years
Trial Updated:
04/09/2025
Locations: Paradise Clinical Research Group LLC, Glendora, California +65 locations
Conditions: Type 2 Diabetes Mellitus, Chronic Kidney Diseases
Subclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease
Recruiting
The aim of this protocol is to assess the presence and severity of primary aldosteronism pathophysiology in patients with type 2 diabetes who have, or are at-risk for developing, chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
04/03/2025
Locations: Brigham and Women's Hospital, Boston, Massachusetts
Conditions: Type 2 Diabetes, Chronic Kidney Diseases
Chronic Kidney Disease-Education (CKD-EDU)
Recruiting
The investigators are conducting a study to see which program better helps older patients with kidney disease choose their treatment. Investigators are also investigating if either program can reduce the number of hospital or emergency room visits in the first 6 months of the study, as well as potentially improve end-of-life care for older adults. Half of the participants will receive Program A, while the other half will receive Program B. Investigators will compare the two groups to see which... Read More
Gender:
ALL
Ages:
75 years and above
Trial Updated:
04/02/2025
Locations: UR Medicine Nephrology - Strong West, Brockport, New York +4 locations
Conditions: Chronic Kidney Diseases
Sit Less, Interact and Move More (SLIMM) 2 Study
Recruiting
* Prolonged sitting (sedentary behavior) is a risk factor for decreased kidney function, obesity, diabetes and mortality. Prolonged sitting is associated with decreased kidney function and increased risk of diabetes, heart disease and death. * In a previous pilot study funded by NIH, it was shown that a Sit Less, Interact and Move More (SLIMM) intervention targeting sedentary behavior in people with kidney disease was able to decrease prolonged sitting but that effect was not sustained. * Theref... Read More
Gender:
ALL
Ages:
20 years and above
Trial Updated:
03/28/2025
Locations: Stanford University, Stanford, California +1 locations
Conditions: Chronic Kidney Diseases, Obesity
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
Recruiting
This is a prospective, randomized, multi-center clinical trial for chronic kidney disease (CKD) patients referred for creation of a new arteriovenous fistula (AVF) in order to assess the safety and effectiveness of SelfWrap, a bioabsorbable perivascular wrap.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/26/2025
Locations: AKDHC Bullhead City, Bullhead City, Arizona +21 locations
Conditions: Chronic Kidney Diseases, End Stage Renal Disease, Arteriovenous Fistula, Hemodialysis Access Failure, ESRD, Vascular Access Complication, Renal Failure, Catheter Complications, Catheter Dysfunction, Renal Insufficiency
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Recruiting
The goal of this study is to better understand the effects of a sodium-glucose transport protein 2 inhibitor, dapagliflozin, added on to standard of care on heart and lung function and circulating metabolites (substances created when our bodies break down food, drugs, or its own tissues) in patients with chronic kidney disease.
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
03/26/2025
Locations: Northwestern University, Chicago, Illinois
Conditions: Chronic Kidney Diseases, Heart Failure With Preserved Ejection Fraction, Kidney Diseases, Heart Failure